Upadacitinib (Rinvoq)

A daily tablet that blocks JAK proteins: how it works, how fast, the checks you need and the risks to know about

6 min read Updated 16 November 2026 5 sources

In short

  • Upadacitinib (brand Rinvoq) is a targeted tablet, not a biologic. It blocks JAK proteins inside cells that switch on inflammation.
  • Some people feel better within days; many within two to eight weeks.
  • NICE recommends it for adults with moderate to severe Crohn's after a biologic has failed or when anti-TNFs are unsuitable. The 2025 BSG guideline also added it.
  • You need regular blood tests (blood counts, liver, cholesterol) and skin checks. Avoid grapefruit.
  • It must not be used in pregnancy or while breastfeeding, so if you can get pregnant you need effective contraception.

Get help if

Call 999 or go to A&E

  • You have chest pain, problems breathing, a drooping face, arm weakness or slurred speech. Crohn's & Colitis UK says to call 999 straight away.
  • You have signs of a severe allergic reaction, such as swelling of your face, lips or throat or difficulty breathing. Crohn's & Colitis UK says to call 999 or get emergency help.

Urgent GP appointment or NHS 111

  • You notice signs of a blood clot in your leg, such as throbbing pain, swelling, and warm, red or darkened skin. Crohn's & Colitis UK says to get medical help straight away. Breathlessness or chest pain needs 999 (see above).
  • You think you have an infection. Contact your GP or NHS 111 and say you take upadacitinib, and let your IBD team know.

In an emergency call 999. For urgent advice call 111 or use 111 online. 1

On this page
  1. What is upadacitinib and how does it work?
  2. Who is it for?
  3. How is it taken, and how quickly does it work?
  4. How well does it work?
  5. What checks will I need?
  6. What side effects can it cause?
  7. Vaccines, pregnancy and breastfeeding
  8. Sources

What is upadacitinib and how does it work?

Upadacitinib belongs to a group of medicines called Janus kinase (JAK) inhibitors. JAKs are proteins inside cells that help switch on the immune response. That helps you fight infections, but in Crohn's it also drives inflammation. Upadacitinib blocks the JAKs, which can calm inflammation in the gut. Because it acts on specific proteins, Crohn's & Colitis UK calls it a targeted medicine.12

Unlike biologics, which are large antibody molecules made by living cells and must be given by drip or injection, upadacitinib is a small molecule made by chemical processes and taken as a tablet. Its brand name is Rinvoq. It is used to treat adults with Crohn's or ulcerative colitis.12

Who is it for?

It can only be prescribed by a hospital specialist. You will usually have tried standard treatments or a biologic first, although you do not need to have tried every option. Your team may suggest it if other treatments have not worked, stopped working, caused bad side effects or are not suitable.1

NICE recommends upadacitinib for adults with moderate to severe Crohn's if a previous biologic has not worked well enough, has stopped working or was not tolerated, or if anti-TNF medicines cannot be used. NICE found that it increased the chance of remission compared with placebo, and that indirect comparisons suggested it works as well as ustekinumab and vedolizumab at a similar or lower cost. As with other medicines, NICE says the least expensive suitable option should be chosen after discussing the choices.3

The 2025 BSG guideline added upadacitinib, along with risankizumab, to the advanced medicines it suggests for settling and maintaining moderate to severe Crohn's. The two sets of UK guidance agree that it is a valid option, although NICE ties its use to people who have already tried a biologic or cannot have an anti-TNF.34

How is it taken, and how quickly does it work?

Upadacitinib is a tablet taken once a day. Swallow it whole with water; do not split, crush or chew it. It can be taken with or without food, ideally at a similar time each day. Your IBD team decides the dose and when to review it. The aim is the lowest dose that keeps your Crohn's under control, and your team may be more cautious if you are 65 or over or at higher risk of heart problems, clots or cancer.1

Avoid grapefruit and grapefruit juice, which can raise the amount of medicine in your body. If you notice pieces of tablet in your poo or stoma bag, tell your IBD team, as it may not be being absorbed properly.1

Upadacitinib can work quickly. Crohn's & Colitis UK says some people feel better within a few days, and many within two to eight weeks. If it has not helped by the end of the starting period, your team may try a little longer before considering a different medicine. Once stopped, it leaves the body within about two to three days.1

How well does it work?

In two large trials, U-EXCEL and U-EXCEED, involving over 1,000 people with moderate to severe Crohn's, more people on upadacitinib were in remission after 12 weeks than on placebo, and more had an improvement in their gut lining on endoscopy. Crohn's & Colitis UK summarises this as about 44 in 100 people on upadacitinib, compared with 25 in 100 on placebo.15

In the follow-on trial, U-ENDURE, people who had responded were more likely to stay in remission at a year if they continued upadacitinib than if they switched to placebo; Crohn's & Colitis UK gives figures of about 57 in 100 compared with 21 in 100. People taking it also reported less diarrhoea, tummy pain and fatigue, and a better quality of life.15

What checks will I need?

Before starting, you may have blood tests for red and white blood cells, liver function and cholesterol. Your team will check for TB (usually with a blood test and chest X-ray), hepatitis and HIV, ask about chickenpox, shingles and cold sores, and make sure your vaccines are up to date. They should also ask whether you have ever had a blood clot.1

During treatment you should have regular check-ups, including blood tests for blood cell counts, cholesterol, liver function and a muscle protein called creatine kinase. Crohn's & Colitis UK suggests avoiding hard exercise just before these tests, as it can raise creatine kinase. Your skin should be checked regularly too.1

What side effects can it cause?

Crohn's & Colitis UK says that in most trials, side effects were about as common with upadacitinib as with placebo. Very common side effects, affecting more than 1 in 10 people, are nose and throat infections and acne. Common side effects include other infections, cough, shingles, a high temperature, feeling sick, weight gain, tummy pain, tiredness, headache, rashes, dizziness or a spinning feeling, and swollen hands or feet.1

In the main trials, shingles was more common at the higher doses than with placebo, and a small number of people (6 out of more than 1,000) developed a tear in the bowel wall (perforation). Infections listed by Crohn's & Colitis UK include flu, cold sores, urine and chest infections and, less often, oral thrush, diverticulitis and blood poisoning (sepsis). People aged 65 or over are more likely to get infections.15

Other risks Crohn's & Colitis UK asks people to know about are non-melanoma skin cancer (which can affect up to 1 in 10 people taking it, and is usually easy to treat), a possible small increase in other cancers, blood clots, and heart attack and stroke. Using sun protection, attending cancer screening and knowing the warning signs all help. Hormonal contraception may add to the risk of clots, so tell your team if you use it.1

Upadacitinib should not be combined with azathioprine or mercaptopurine. It is safe to take with steroids or 5-ASA medicines. Some antibiotics, antifungal medicines and the epilepsy medicine phenytoin can affect how it works, so always check before starting anything new.1

Vaccines, pregnancy and breastfeeding

Live vaccines should not be given while you take upadacitinib, and Crohn's & Colitis UK says you may need to wait three months after stopping. Non-live vaccines are fine, though they may work less well. Crohn's & Colitis UK says both doses of the non-live shingles vaccine should be offered to anyone over 18 taking upadacitinib.1

Upadacitinib must not be taken in pregnancy, because animal studies suggest it may harm an unborn baby. If you could get pregnant, use effective contraception during treatment and for at least four weeks after stopping, and talk to your team well before trying for a baby. It should not be taken while breastfeeding. If you find you are pregnant, contact your IBD team straight away, but do not stop the medicine until you have spoken to them.1

Sources

This article is written in our own words from these sources. Each number in the text points to one of them.

  1. Crohn's & Colitis UK Upadacitinib Read on the Crohn's & Colitis UK website: Upadacitinib
  2. Crohn's & Colitis UK Biologic medicines and other targeted treatments Guide, Jul 2023 Read on the Crohn's & Colitis UK website: Biologic medicines and other targeted treatments
  3. NICE Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905) Guideline, Jun 2023 Read on the NICE website: Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
  4. Frontline Gastroenterology (via PMC) Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease Guide, Nov 2025 Read the paper: Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease
  5. New England Journal of Medicine Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE) Study, May 2023 Read the paper: Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE)